Articles tagged with Drug Candidates
Researchers at UC San Diego developed a high-throughput 3D bioprinting technology that can produce 96-well arrays of living human tissue samples in just 30 minutes, accelerating preclinical drug screening and disease modeling. This could potentially reduce the time and cost associated with drug development.
Researchers at the University of Liverpool have developed a long-acting injectable therapy using an existing and cheap drug, showing promise in treating COVID-19. The formulation uses nanoparticle technology to deliver the drug sustainably over several months.
A team of researchers identified 37 substances that bind to the main protease of SARS-CoV-2, a promising starting point for COVID-19 drugs. Seven substances inhibit the protein's activity, with two showing high antivirality and good cell compatibility.
Chemists have developed a method to synthesize complex, three-dimensional molecules using light energy transfer, expanding the range of molecules for new drug development. The novel approach uses commercially available starting materials and demonstrates broad applicability.
The Endocrine Society emphasizes the need to study biological differences between females and males in medicine and research to improve public health. Studies have shown that SARS CoV-2 infection disproportionately affects men, while failing to consider sex differences can lead to failure of promising drug candidates.
A research team has discovered two families of active substances that can block the replication of SARS-CoV-2 by targeting its main protease enzyme. The drug candidates show promise for therapeutic development, but extensive clinical trials are still required.
OYE Therapeutics is developing a new life-saving strategy to reduce mortality and morbidity resulting from battlefield injuries. The company, in partnership with USU and HJF, aims to enhance acute pain control at the point-of-injury through its drug product pipeline.
Researchers designed a simple screening assay based on competitive binding to identify peptide candidates with high binding affinity for ubiquitin. The dimers of cyclic peptides were found to be more potent than control peptides and induced cell death in live cancer cell lines.
Ovarian clear cell carcinoma (OCCC) remains a rare subtype with poor prognosis. Simvastatin efficiently controlled OCCC proliferation and migration, demonstrating potential as a candidate drug.
Researchers analyze molecular dynamics of proposed COVID-19 drug candidates to understand their interactions with target proteins in human cells. They found that certain parts of the molecules can move more easily once hydrated, which could influence how efficiently a drug takes on shapes associated with different biological functions.
Researchers at the University of Chicago used computational simulations to understand how remdesivir works against SARS-CoV-2. They found that remdesivir binds strongly to the virus and destabilizes its protein complex, reducing replication. This study provides insights into the molecular mechanism of remdesivir and its potential for e...
A team of international researchers found that certain FAK inhibitors remain bound to the protein for a long time, causing a structural change that inhibits cancer cell mobility. Computer simulations predicted the kinetics of binding well, allowing for more accurate simulation of drug dissociation rates.
Researchers have secured a £1.6 million grant to develop M102, a potential breakthrough in treating motor neuron disease (MND). The drug's neuroprotective properties were discovered by the University of Sheffield's Institute for Translational Neuroscience (SITraN), which will now advance its translational development.
Scientists developed a machine-learning framework to identify potential repurposed drugs for diseases, using massive amounts of data from patient care records. The analysis suggested six candidates, including metformin and escitalopram, which are currently being tested.
A comprehensive review of plant natural products reveals 459 compounds with antibacterial activity, providing promising candidates for new antibiotic discovery. The review, led by Cassandra Quave, aims to facilitate the search for effective drugs against antibiotic-resistant pathogens.
Researchers at MedUni Vienna's Institute of Pharmacology have isolated a beetroot peptide that inhibits prolyl oligopeptidase, an enzyme involved in the breakdown of protein hormones in the body. The study suggests that this peptide could be a promising drug candidate for treating neurodegenerative and autoimmune diseases.
Researchers at Michigan State University have developed a deep learning model to predict the binding sites of known protease inhibitors targeting the SARS-CoV-2 main protease. The model can help drug developers prioritize promising candidates and save time and money in the early stages of drug development.
University of New Mexico researchers have identified three medications with potential to treat SARS-CoV-2 infection: amodiaquine, zuclophentixol, and nebivolol. These drugs showed promise in test tube experiments and could be combined with remdesivir for a more potent attack.
A new drug candidate, MPH-220, has been developed to target muscle spasticity after stroke and nervous system defects. By inhibiting the effector protein of muscle contraction, it may alleviate symptoms with a single pill per day.
A new assay using HEPATOPAC model identifies drugs with high DILI risk, showing high sensitivity and specificity. BioIVT's advanced in vitro liver model provides a promising solution for preclinical DILI risk assessment.
Researchers repurpose anti-malarial compounds to target the intestinal parasite Cryptosporidium, killing it in cell cultures and immunocompromised mice. The compounds work by inhibiting an enzyme responsible for protein production within the parasite.
A polygenic risk score has been developed to predict drug-induced liver injury, using genomic data and organoid models. The score can identify patients at risk of liver damage, allowing for safer medication choice and dosage.
A $11.4 million NIH grant has funded the advancement of a novel drug candidate, SBP-9330, targeting a neuronal signaling pathway underlying addictive behaviors to treat nicotine addiction. The drug is expected to be effective in reducing nicotine self-administration and may broaden its indication to other types of addiction.
Researchers have developed novel Selenium-based compounds that can stabilize the SOD1 protein, which causes ALS. These compounds show improved in vitro therapeutic effects and demonstrate disease onset delay in an ALS mouse model. The findings hold promise for a new class of drug candidates for ALS treatment.
Researchers used machine learning to correlate information on drugs, genes, and diseases, identifying 63 drugs targeting 31 genes as potential candidates for psychiatric and neurological treatment. The approach will also be applied to search for correlations between drugs, genes, and COVID-19.
A Nature study identified 21 existing drugs that stop SARS-CoV-2 replication, including four that work synergistically with remdesivir. These compounds have potential for COVID-19 treatment and could provide affordable alternatives if the virus becomes drug-resistant.
Researchers at Istituto Italiano di Tecnologia have discovered a novel chemical compound that shows promise in treating core symptoms of brain disorders such as Down syndrome and autism. The new compound selectively blocks the transporter NKCC1, which is dysregulated in these conditions.
Researchers identify four promising antiviral drug candidates that block SARS-CoV-2 replication by targeting the main protease enzyme. The most effective compound, GC-376, demonstrates potent chemical and structural interactions with the viral protein, making it a potential candidate for repurposing as a COVID-19 treatment.
Scientists discovered a common molecular pathway in women who experience preterm labor and are developing new treatments using FDA-approved drugs. The research found that combined administration of nebivolol and N6022 can almost completely halt contractions, improving birth outcomes.
A NUS-led team has developed an artificial intelligence platform called IDentif.AI to rapidly identify optimal drug combination therapies for infectious diseases. The platform uses machine learning to examine billions of possible combinations and doses, resulting in unprecedented speed and accuracy in discovering new treatments.
A first-in-human study of a drug candidate targeting brain inflammation has shown promising results, supporting its further development for treating acute brain injuries. The study, conducted by a team from the University of Kentucky and other institutions, found that MW189 was safe and well-tolerated in healthy volunteers.
An international team of researchers has identified six potential COVID-19 treatment candidates after testing over 10,000 compounds. The targeted therapeutics were found to be effective in inhibiting the main protease enzyme of the virus.
Researchers at McGill University receive funding to develop a rapid diagnostic device for COVID-19 testing, screen approved drugs for efficacy against the virus, and study key genetic markers of immune response. The goal is to understand how coronaviruses evade human immunity and develop effective interventions to halt the pandemic.
Researchers developed a cancer-drug candidate called OxaliTEX that stops tumor growth entirely and delivers more cancer-busting power than many commonly used chemotherapy drugs. OxaliTEX has fewer toxic side effects and is more effective in overcoming resistance compared to existing platinum-based treatments like carboplatin.
Recent technical developments and restrictions on chemicals have renewed interest in natural product drug discovery. Essential oil components show promise as sources of new drugs due to their unique properties and potential therapeutic applications.
A computational study identified lansoprazole and 12 other FDA-approved drugs that reduce inflammation and may prevent preterm birth. The drugs act on biological pathways affecting the immune response, which is implicated in preterm birth. Further testing is needed to confirm their effectiveness.
Researchers found that hiring managers perceive candidates with self-absorbed or overly opinionated social media profiles as less suitable for employment. The study also discovered that content suggesting drug or alcohol use has a smaller impact on perceptions of employment suitability.
Researchers developed a comprehensive multi-Organ-on-a-Chip platform to bridge the gap in current limitations in drug development. The system enabled accurate modeling of human pharmacokinetic and pharmacodynamic parameters for tested drugs, mimicking real-world human responses.
Researchers at Harvard Medical School have launched a project to develop preclinical drug candidates that selectively block nociceptor activity, offering an alternative to opioid-based medications. The STOP PAIN consortium combines experimental and AI-driven approaches to address the critical public health need for new pain treatments.
Researchers created a Liver-Chip using Organs-on-Chips technology to predict liver toxicity across species. The platform accurately assesses the liver-specific effects of various drugs on liver cells from rat, dog, and human sources.
Emory researchers have secured a $15.89 million NIAID contract to test the antiviral drug EIDD-2801 in human trials. The goal is to develop a better drug against influenza, which kills an average of 20,000 people annually in the US. EIDD-2801 has shown promising results in animal models and is effective against multiple RNA-based viruses.
A recent poll shows that almost 9 in 10 Canadians support a national pharmacare plan providing equal access to medications. Most federal parties are offering major policy proposals to introduce national pharmacare, but long-term thinking is crucial to its success.
Quinacrine repurposed with cisplatin synergizes to reduce cancer growth, increasing median time to tumor volume by 12 days; enhances apoptosis and inhibits autophagy in HNSCC cells.
A new study reveals that many cancer drug candidates fail in clinical trials due to off-target effects, rather than targeting essential molecular mechanisms. This unexpected finding challenges over 180 previous reports on the importance of specific proteins for cancer cell survival.
The study demonstrated the potential of body-on-a-chip systems to transform the drug discovery process by accurately predicting cardiotoxic mechanisms and replicating in vivo results. The findings support the use of in vitro models to evaluate temporal pharmacokinetic/pharmacodynamic relationships.
The University of Illinois Chicago is collaborating with TB Alliance to develop new clinical-stage drug candidates for treating tuberculosis, a bacterial infection resistant to available antibiotics. The five-year research project aims to produce two new treatments, with UIC receiving up to $9 million in funding.
Boehringer Ingelheim and the University of Dundee have extended their collaboration to develop novel protein degradation medicines targeting cancer-causing proteins. The structure-based design approach has yielded a highly potent and selective drug candidate, making it freely available via Boehringer Ingelheim's open innovation portal.
Researchers discovered that aging in nematodes is partially programmed and can be therapeutically reversed by several FDA-approved drugs. The study identified 10 compounds that slow down aging, including six previously documented with anti-aging potential.
Researchers identified 10 FDA-approved drugs that can slow down aging in nematodes, with six having previously documented anti-aging potential. These compounds have the advantage of already passing clinical trials and can be used off-label as anti-aging drugs, targeting life-extending compounds.
Researchers used long-lived roundworms to identify new anti-aging compounds among FDA-approved drugs. They found that these compounds can slow down aging in nematodes and may have therapeutic potential for humans.
Researchers developed a new method to assess medicines' actions by matching them to unique protein receptors, potentially speeding up drug development. The method reduces time and labor in finding the right response to drug candidates by several orders of magnitude.
PRI-002, a new Alzheimer's drug candidate, has successfully completed Phase I clinical research, demonstrating improved cognitive performance in human trials. The compound destroys toxic oligomers without involving the immune system, offering a promising approach to treating Alzheimer's disease.
Researchers developed a drug candidate that can reverse mucosal barrier damage caused by HIV. The recombinant molecule rfhSP-D prevented HIV transmission and restored vaginal tissue integrity. This finding presents a promising approach to creating a safe and effective topical anti-HIV microbicide.
Researchers at Stanford University School of Medicine have created a blood test that can flag the disease, which currently lacks a standard diagnostic test. The test successfully identified participants in a study with chronic fatigue syndrome and is being used to screen for potential drugs that may help treat the condition.
Researchers have identified a common species of seaweed, Laminaria ochroleuca, as a rich source of bacteria with antimicrobial and anticancer activities. The study reveals that extracts from these Actinobacteria inhibited growth of various pathogens and showed selective anticancer activity.
Researchers at LSTM and University of Buea developed new Loa loa infection models to assess the safety of anti-filarial drugs. These models have enabled the prioritization of drug candidates for preclinical development, targeting onchocerciasis while avoiding loiasis adverse reactions.
A new drug candidate, givosiran, has shown promising results in treating acute porphyria by preventing attacks and reducing hemin need by up to 83%, according to a recent clinical trial. The study's lead author notes that the treatment can effectively prevent acute attacks in seriously afflicted patients with limited options.
Researchers have developed a novel fully synthetic and rationally designed anti-Wolbachia drug, AWZ1066S, which could potentially treat onchocerciasis and lymphatic filariasis. The compound has shown high specificity and potency against Wolbachia, with the potential to shorten treatment times from weeks to days.
Researchers have developed a highly specific anti-Wolbachia drug candidate that could provide a safe oral treatment for worm infections in just 7 days. The new therapy has superior efficacy and favorable drug properties compared to existing options, which typically take 4-6 weeks to treat similar conditions.
Researchers explored umbelliferone-based derivatives as potent monoamine oxidase inhibitors. The compounds exhibited significant MAO-A and hMAO-B inhibitory potential, with some also showing antioxidant properties.